0On record
No trial on ClinicalTrials.gov lists this combination
We found no registered interventional trial on
ClinicalTrials.gov that administers GHK-Cu, BPC-157 and TB-500 together. The individual
compounds may have trials of their own — those are listed below — but a
trial of one ingredient does not tell you what the mixture does.
That is not a claim the combination is harmful or useless. It means the
specific question has not been asked on the record.
The ingredients, separately
GHK-Cu
Copper peptide
One of the few where the trials roughly match the marketing — skin. The hair-growth claims are not what's being tested.
Studied on its own
2
Registered trials
BPC-157
Body Protection Compound 157 · Pentadecapeptide
Marketed for four uses. The two registered human trials both study muscle injury, and one is still recruiting.
Studied on its own
2
Registered trials
TB-500
Thymosin Beta-4 fragment
The one human trial under this name is a heart study. Not a single registered trial tests it for the injury recovery it's sold for.
Studied on its own
1
Registered trials
—Read this
Why combinations are studied separately
Two compounds given together can interact — in how they are absorbed, how long they last, or what they do at the same receptor. That is why regulators treat a fixed combination as its own product requiring its own trials. CagriSema is the example on this site of a combination developed and tested as one thing.